Secondary Logo

Institutional members access full text with Ovid®

Current clinical applications of antimullerian hormone

Merlotti, Lindsaya; Kuohung, Wendyb; Rinehart, Johna

Current Opinion in Endocrinology, Diabetes and Obesity: December 2018 - Volume 25 - Issue 6 - p 373–376
doi: 10.1097/MED.0000000000000441

Purpose of review Determine if literature supports the use of anti-Müllerian hormone (AMH) as a useful biomarker of reproductive potential when cumulative live birth rates (CLBRs) per retrieval are used as the outcome variable.

Recent findings Advances in technology used in in-vitro fertilization (IVF) permit the use of single embryo transfer to achieve expected pregnancy success rates. Many IVF cycles result in the creation of more than a single embryo suitable for transfer per oocyte retrieval. Cryopreservation permits subsequent use of other embryos with no loss in total reproductive potential from single retrievals. Therefore, an emerging concept in IVF is the CLBR per retrieval as an indicator of the patient's reproductive potential. Using the total reproductive potential from a single retrieval may help patients decide on IVF. As such, any predictor of success that relies upon the live birth rate for a single transfer, as opposed to CLBR per retrieval, is inadequate to estimate the true reproductive potential for patient. AMH has been proposed as a biomarker for reproductive potential, but most studies have correlated an AMH value to a single embryo transfer.

Summary A more appropriate way to use AMH levels may be to correlate the AMH with CLBR per retrieval. AMH may thus prove to be a useful biomarker when counseling patients about what to expect from their treatment.

aDepartment of Reproductive Endocrinology, Evanston, Illinois

bDepartment of Reproductive Endocrinology, Boston, Massachusetts, USA

Correspondence to John Rinehart, MD, PhD, JD, 2500 Ridge Ave, Suite 308, Evanston, IL 60201, USA. Tel: +1 847 869 7777; e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.